Literature DB >> 20180762

TGR5 as a therapeutic target for treating obesity.

Min Zhong1.   

Abstract

TGR5 (also known as GPBAR1, M-BAR, BG37, hGPCR19, and AXOR 109) is a specific membrane G-protein-coupled receptor (GPCR) of bile acids (BAs). It has recently become an attractive therapeutic target for the prevention and/or the treatment of obesity and its highly associated Type II diabetes and metabolic syndrome. It has also been implicated in many other inflammatory, cardiovascular, neurological, and hepatic diseases. This review briefly describes the biological rationale of TGR5 as an attractive therapeutic target and summarizes some recent efforts on the development of TGR5 modulators.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180762     DOI: 10.2174/156802610790980576

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  11 in total

1.  TGR5 in the Cholangiociliopathies.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 2.  The bile acid TGR5 membrane receptor: from basic research to clinical application.

Authors:  Henri Duboc; Yvette Taché; Alan F Hofmann
Journal:  Dig Liver Dis       Date:  2014-01-09       Impact factor: 4.088

Review 3.  Interaction of gut microbiota with bile acid metabolism and its influence on disease states.

Authors:  Alexander Khoruts; Michael J Sadowsky; Christopher Staley; Alexa R Weingarden
Journal:  Appl Microbiol Biotechnol       Date:  2016-11-25       Impact factor: 4.813

4.  Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.

Authors:  David W Piotrowski; Kentaro Futatsugi; Joseph S Warmus; Suvi T M Orr; Kevin D Freeman-Cook; Allyn T Londregan; Liuqing Wei; Sandra M Jennings; Michael Herr; Steven B Coffey; Wenhua Jiao; Gregory Storer; David Hepworth; Jian Wang; Sophie Y Lavergne; Janice E Chin; John R Hadcock; Martin B Brenner; Angela C Wolford; Ann M Janssen; Nicole S Roush; Joanne Buxton; Terri Hinchey; Amit S Kalgutkar; Raman Sharma; Declan A Flynn
Journal:  ACS Med Chem Lett       Date:  2012-11-09       Impact factor: 4.345

5.  Plasma bile acids are not associated with energy metabolism in humans.

Authors:  Gemma Brufau; Matthias J Bahr; Bart Staels; Thierry Claudel; Johann Ockenga; Klaus Hw Böker; Elizabeth J Murphy; Kris Prado; Frans Stellaard; Michael P Manns; Folkert Kuipers; Uwe Jf Tietge
Journal:  Nutr Metab (Lond)       Date:  2010-09-03       Impact factor: 4.169

6.  Identification of a Crosstalk among TGR5, GLIS2, and TP53 Signaling Pathways in the Control of Undifferentiated Germ Cell Homeostasis and Chemoresistance.

Authors:  Laura Thirouard; Hélène Holota; Mélusine Monrose; Manon Garcia; Angélique de Haze; Christelle Damon-Soubeyrand; Yoan Renaud; Jean-Paul Saru; Alessia Perino; Kristina Schoonjans; Claude Beaudoin; David H Volle
Journal:  Adv Sci (Weinh)       Date:  2022-04-18       Impact factor: 17.521

7.  Structural modifications that increase gut restriction of bile acid derivatives.

Authors:  Ali Nakhi; Henry L Wong; Melissa Weldy; Alexander Khoruts; Michael J Sadowsky; Peter I Dosa
Journal:  RSC Med Chem       Date:  2021-02-12

8.  Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells.

Authors:  Alexander A Goldberg; Vladimir I Titorenko; Adam Beach; J Thomas Sanderson
Journal:  PeerJ       Date:  2013-08-08       Impact factor: 2.984

9.  Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect.

Authors:  Hua Cao; Zhi-Xiang Chen; Kai Wang; Meng-Meng Ning; Qing-An Zou; Ying Feng; Yang-Liang Ye; Ying Leng; Jian-Hua Shen
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

10.  Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice.

Authors:  Sooghee Chang; Youn-Hee Kim; Young-Joo Kim; Young-Woo Kim; Sungyoon Moon; Yong Yook Lee; Jin Sun Jung; Youngsoo Kim; Hi-Eun Jung; Tae-Joo Kim; Taek-Chin Cheong; Hye-Jung Moon; Jung-Ah Cho; Hang-Rae Kim; Dohyun Han; Yirang Na; Seung-Hyeok Seok; Nam-Hyuk Cho; Hai-Chon Lee; Eun-Hee Nam; Hyosuk Cho; Murim Choi; Nagahiro Minato; Seung-Yong Seong
Journal:  Front Immunol       Date:  2018-09-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.